Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Real-World Evidence Could Speed Development Of Drugs Offering Incremental Improvements

Executive Summary

US FDA Commissioner Gottlieb says common diseases need new treatments and argues streamlining trials may pique industry interest.

Related Content

US Throws Drug Pricing Weight Around, But Still Depends On Pharma Decisions
Drug/Software Combo Platform Coming Soon To US FDA, Gottlieb Says
US FDA Amps Up "Name And Shame" Approach To Thwart Anti-Generic Tactics
FDA Approving Complex Generics Pre-ANDA Meeting Requests At Higher Rates
US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products
Gene Therapy 'Cassettes' Could Speed, Cheapen Manufacturing, Gottlieb Says
Q&A With US FDA Commissioner Scott Gottlieb
FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development
FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On
In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts